- Q1 2024 DiaSorin SpA Earnings Call TranscriptMay 10, 2024$107.4Earnings
- Q3 2023 DiaSorin SpA Earnings Call TranscriptNov 03, 2023$87.45Earnings
- Half Year 2023 DiaSorin SpA Earnings Call TranscriptJul 27, 2023$96Earnings
- Q1 2023 DiaSorin SpA Earnings Call TranscriptMay 09, 2023$119.74Earnings
- Full Year 2022 DiaSorin SpA Earnings Call TranscriptMar 27, 2023$111.33Earnings
- Cytek Biosciences Inc To Acquire Flow Cytometry and Imaging Business From DiaSorin- M&A Call TranscriptFeb 13, 2023
- Q3 2022 DiaSorin SpA Earnings Call TranscriptOct 27, 2022$107Earnings
- Q2 2022 DiaSorin SpA Earnings Call TranscriptAug 03, 2022$144.11Earnings
- Q1 2022 DiaSorin SpA Earnings Call TranscriptMay 06, 2022$129Earnings
- Q4 2021 DiaSorin SpA Earnings Call TranscriptMar 16, 2022$130Earnings
- DiaSorin SpA Investor Day TranscriptDec 17, 2021
- Q3 2021 DiaSorin SpA Earnings Call TranscriptNov 11, 2021$220.95Earnings
- Q2 2021 DiaSorin SpA Earnings Call TranscriptJul 30, 2021$203.44 (+1.72%)Earnings
- Q1 2021 DiaSorin SpA Earnings Call TranscriptMay 14, 2021$173.25Earnings
- DiaSorin SpA to Acquire Luminex Corp Call TranscriptApr 12, 2021
- Q4 2020 DiaSorin SpA Earnings Call TranscriptMar 11, 2021$219Earnings
- Q3 2020 DiaSorin SpA Earnings Call TranscriptNov 11, 2020$183Earnings
- Q2 2020 DiaSorin SpA Earnings Call TranscriptJul 30, 2020$202.18Earnings
- Q1 2020 DiaSorin SpA Earnings Call TranscriptMay 13, 2020$169.66Earnings
- Q4 2019 DiaSorin SpA Earnings Call TranscriptMar 11, 2020$118.43 (-3.34%)Earnings
- Q3 2019 DiaSorin SpA Earnings Call TranscriptNov 06, 2019$114.75Earnings
- Q2 2019 DiaSorin SpA Earnings Call TranscriptJul 31, 2019$114.75Earnings
- DiaSorin SpA Investor Day TranscriptJun 11, 2019
- Q1 2019 DiaSorin SpA Earnings Call TranscriptMay 09, 2019$100.1Earnings
- Q4 2018 DiaSorin SpA Earnings Call TranscriptMar 14, 2019$95.67Earnings
DiaSorin SpA Investor Day Transcript
(foreign language)
So now I will switch to English. Welcome to everybody who is connected in streaming. I will give a presentation today where I'm going to be discussing the strategic setup of the company, market conditions and then our Chief Financial Officer, Mr. Pedron, is going to join me on the podium and he's going to take you through the numbers.
So I would like to start talking about who we are. And if you remember, the last meeting we had was in 2019. And in 2019, we confirmed the fact that this company to survive, thrive and be successful has to be a specialty company. And we need to be a specialty company because competition is very tough, because the environment is very complicated and because this space is actually consolidated by companies which are 10x the size of DiaSorin. So the only way for a company like ours to thrive and continue to be successful is to stay focused in areas that are complicated that do require innovation and innovative technologies. This has been for the last 20 years. And what we are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)